DEA Rescheduling Legal Challenges: State Lawsuits and Federal Cannabis Policy

Executive Summary

The Drug Enforcement Administration's proposal to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act has triggered a multi-front legal battle that could reshape federal drug policy and the $30 billion U.S. cannabis industry. Since the DEA published its Notice of Proposed Rulemaking in May 2024, more than a dozen lawsuits have been filed by state attorneys general, cannabis operators, patient advocacy groups, and industry associations challenging various aspects of the rescheduling process. The most recent development came in May 2026, when Indiana Attorney General joined a coalition of conservative states seeking to block the rescheduling entirely, arguing it exceeds federal authority and contradicts international treaty obligations. Simultaneously, cannabis businesses and medical marijuana patients have filed separate legal challenges arguing the DEA's proposed Schedule III placement doesn't go far enough and maintains unnecessary restrictions on a substance now legal for medical use in 38 states and recreational use in 24 states. These parallel legal challenges—some seeking to stop rescheduling, others demanding full descheduling—will likely take years to resolve through the federal court system and could ultimately reach the Supreme Court.

Why This Matters

The outcome of these legal challenges will directly affect 250 million Americans living in states with legal cannabis programs, determine the fate of 15,000+ licensed cannabis businesses, and reshape a market projected to reach $57 billion by 2030. For the estimated 5.8 million registered medical marijuana patients nationwide, the legal uncertainty threatens access to medications that treat conditions ranging from chronic pain to epilepsy to PTSD. According to the National Cannabis Industry Association, the current Schedule I classification costs cannabis businesses an estimated $1.8 billion annually in excess federal taxes under Internal Revenue Code Section 280E, which prohibits business deductions for trafficking in Schedule I or II controlled substances. Rescheduling to Schedule III would eliminate this tax burden, potentially reducing retail prices by 15-25% and improving patient affordability. The legal challenges also carry profound implications for state sovereignty and federalism. Twenty-four states have legalized adult-use cannabis despite federal prohibition, creating a constitutional tension that these lawsuits force courts to address directly. The pharmaceutical industry watches closely, as Schedule III classification would enable FDA-approved cannabis-derived medications to enter the market more easily, potentially displacing state-licensed dispensary products. Research institutions stand to benefit from reduced regulatory barriers, as Schedule III substances face fewer restrictions for clinical trials than Schedule I drugs. The DEA itself faces an institutional crossroads, as these lawsuits challenge the agency's scientific methodology, administrative procedures, and fundamental authority to classify substances contrary to state medical determinations.

Background and History

The legal battle over cannabis rescheduling represents the culmination of a 54-year conflict between federal prohibition and evolving state policies that began when Congress passed the Controlled Substances Act in 1970.

The Controlled Substances Act Framework (1970)

President Richard Nixon signed the Controlled Substances Act into law on October 27, 1970, as Title II of the Comprehensive Drug Abuse Prevention and Control Act. The statute, codified at 21 U.S.C. § 801 et seq., established five schedules of controlled substances based on medical utility, abuse potential, and safety. Cannabis was placed in Schedule I—the most restrictive category—alongside heroin, LSD, and peyote. Schedule I designation requires three findings: the substance has high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The DEA received authority to add, remove, or reschedule substances through administrative rulemaking under 21 U.S.C. § 811, subject to scientific and medical evaluations from the Department of Health and Human Services.

Early Rescheduling Petitions (1972-2012)

The National Organization for the Reform of Marijuana Laws filed the first cannabis rescheduling petition in May 1972, just 19 months after the CSA took effect. The petition languished for 16 years before DEA Administrative Law Judge Francis Young issued a landmark 1988 ruling finding that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man" and recommended moving it to Schedule II. DEA Administrator John Lawn rejected Young's recommendation in December 1989, a decision upheld by the D.C. Circuit Court of Appeals in 1994. Subsequent petitions filed in 1995, 2002, and 2011 met similar fates, with the DEA consistently maintaining that cannabis lacked accepted medical use despite growing state-level medical marijuana programs.

The Cole Memo Era (2013-2018)

Deputy Attorney General James Cole issued guidance on August 29, 2013, directing federal prosecutors to deprioritize enforcement against state-legal cannabis operations that complied with robust regulatory frameworks. The Cole Memorandum established eight enforcement priorities, including preventing distribution to minors and diversion to prohibition states. This policy created a fragile détente between federal law and state programs, though it carried no legal force and could be rescinded at any time. Attorney General Jeff Sessions formally withdrew the Cole Memo on January 4, 2018, though practical enforcement patterns changed little.

The 2018 Farm Bill and Hemp Legalization

President Donald Trump signed the Agriculture Improvement Act of 2018 into law on December 20, 2018, removing hemp—defined as cannabis with no more than 0.3% delta-9 THC on a dry weight basis—from the CSA's definition of marijuana. This created a legal distinction between hemp and marijuana based solely on THC concentration, opening a regulatory gap that enabled the proliferation of hemp-derived cannabinoid products including delta-8 THC, THCA, and other intoxicating compounds. The hemp carveout demonstrated Congress's recognition that not all cannabis posed equivalent risks, undermining the scientific basis for Schedule I classification.

Biden Administration Review (2022-2024)

President Joe Biden issued a presidential pardon for federal simple marijuana possession offenses on October 6, 2022, and directed HHS Secretary Xavier Becerra and Attorney General Merrick Garland to "expeditiously" review cannabis scheduling. HHS completed its scientific and medical evaluation in August 2023, recommending rescheduling to Schedule III based on findings that cannabis has accepted medical use, lower abuse potential than Schedule I or II substances, and moderate to low physical dependence liability. The DEA received HHS's recommendation on August 30, 2023, triggering the agency's independent review process.

Notice of Proposed Rulemaking (May 2024)

The DEA published its Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, formally proposing to reschedule marijuana and marijuana-related substances from Schedule I to Schedule III. The NPRM opened a 60-day public comment period that was later extended to 90 days due to overwhelming response volume. The agency received more than 43,000 public comments—the most in DEA history for a rescheduling action. The DEA scheduled a two-day public hearing for December 2024, where 57 witnesses testified representing medical associations, patient advocates, law enforcement, cannabis businesses, and addiction specialists. Administrative Law Judge John Mulrooney presided over the hearing, which generated more than 1,200 pages of transcript.

Legal Challenges Begin (June 2024-Present)

The first lawsuit challenging the rescheduling process was filed on June 3, 2024, by a coalition of cannabis industry plaintiffs in the U.S. District Court for the District of Columbia, arguing the DEA's proposed Schedule III classification violated the Administrative Procedure Act by ignoring evidence supporting full descheduling. Within weeks, multiple additional lawsuits emerged from different stakeholder groups with conflicting objectives—some seeking to accelerate rescheduling or demand descheduling, others seeking to block any schedule change. By May 2026, when Indiana Attorney General joined a multi-state lawsuit opposing rescheduling, federal courts faced more than 15 active cases challenging various aspects of the DEA's process and proposed outcome.

Key Players

Drug Enforcement Administration

The DEA serves as the defendant in virtually all rescheduling litigation, defending its administrative process and scientific determinations. Administrator Anne Milgram oversees the agency's response to legal challenges while simultaneously managing the ongoing rescheduling proceeding. The DEA's Office of Diversion Control handles the technical aspects of controlled substance scheduling, while the Office of Chief Counsel manages litigation strategy. The agency faces the delicate task of defending its authority to reschedule cannabis while maintaining that Schedule III—not descheduling—represents the appropriate classification based on current evidence.

Department of Health and Human Services

HHS provided the scientific and medical evaluation that forms the foundation of the DEA's rescheduling proposal. The Food and Drug Administration conducted the eight-factor analysis required under 21 U.S.C. § 811(c), evaluating cannabis's abuse potential, pharmacology, scientific evidence, history and current pattern of abuse, scope and significance of abuse, and risk to public health. HHS's August 2023 recommendation carries significant legal weight, as the CSA requires the DEA to accept HHS's scientific and medical findings as binding on questions of medical utility and health risks. Assistant Secretary for Health Rachel Levine signed the final recommendation transmitted to DEA.

Multi-State Coalition Opposing Rescheduling

A coalition of 12 state attorneys general filed suit in the U.S. Court of Appeals for the Fifth Circuit in March 2025, seeking to block cannabis rescheduling entirely. The coalition, led by Nebraska Attorney General Mike Hilgers and Kansas Attorney General Kris Kobach, argues that rescheduling exceeds federal authority, violates the Single Convention on Narcotic Drugs of 1961, and undermines state law enforcement efforts. Indiana Attorney General joined the lawsuit in May 2026, bringing the coalition to 13 states. The states argue that the DEA ignored evidence of cannabis's high abuse potential and that HHS's medical evaluation was scientifically flawed. All coalition states maintain prohibition of recreational cannabis, and most prohibit medical marijuana as well.

Cannabis Industry Plaintiffs

Multiple cannabis businesses and industry associations have filed separate lawsuits arguing the DEA's Schedule III proposal doesn't go far enough. The Coalition for Cannabis Scheduling Reform, representing more than 1,200 licensed operators across 35 states, filed suit in the D.C. Circuit in July 2024, demanding full descheduling or, alternatively, Schedule IV or V classification. The National Cannabis Industry Association filed a parallel action in August 2024. These plaintiffs argue that cannabis's widespread state-level legalization, extensive safety record, and accepted medical use require removal from the CSA entirely or placement in the least restrictive schedule. Industry plaintiffs emphasize that Schedule III maintains criminal penalties for state-legal operations and preserves federal-state legal conflicts.

Patient Advocacy Organizations

Americans for Safe Access, the nation's largest medical marijuana patient advocacy organization, intervened in multiple rescheduling lawsuits to represent the interests of the 5.8 million registered medical cannabis patients. The organization argues that any schedule placement violates patients' constitutional rights to access physician-recommended medicine and that the DEA's process failed to adequately consider patient testimony and real-world medical evidence. The Epilepsy Foundation and Veterans Action Council filed amicus briefs supporting rescheduling, citing clinical evidence of cannabis's efficacy for seizure disorders and PTSD.

Medical and Scientific Organizations

The American Medical Association filed comments during the NPRM process supporting rescheduling to facilitate research, though stopping short of endorsing specific schedule placement. The American Academy of Neurology submitted evidence of cannabis's medical utility for multiple sclerosis spasticity and certain epilepsy syndromes. The National Institute on Drug Abuse provided data on abuse potential and addiction rates. These organizations generally support rescheduling to reduce research barriers while emphasizing the need for continued study of long-term health effects.

Pharmaceutical Industry

Major pharmaceutical companies have remained largely silent in public filings but watch the litigation closely. Schedule III classification would enable FDA approval of cannabis-derived medications through the standard New Drug Application process, potentially allowing pharmaceutical companies to develop and market standardized cannabis products. This could disrupt the state-licensed dispensary model and shift cannabis commerce toward the traditional pharmaceutical distribution system.

Legal and Regulatory Framework

The legal challenges to DEA cannabis rescheduling invoke multiple federal statutes, constitutional provisions, and administrative law doctrines that collectively determine the scope of agency authority and judicial review. The Controlled Substances Act establishes the statutory framework at 21 U.S.C. § 811, which authorizes the Attorney General (who has delegated this authority to the DEA Administrator) to add, remove, or reschedule substances. The statute requires the DEA to request a scientific and medical evaluation from HHS and to consider eight factors: actual or relative potential for abuse; scientific evidence of pharmacological effect; current scientific knowledge regarding the substance; history and current pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance. Critically, 21 U.S.C. § 811(b) provides that HHS's recommendations on scientific and medical matters are binding on the DEA. The Administrative Procedure Act, codified at 5 U.S.C. § 551 et seq., governs the rescheduling process and provides the legal standard for judicial review. Under 5 U.S.C. § 706, courts must set aside agency actions that are "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law." The APA requires agencies to examine relevant data, articulate a rational connection between facts found and choices made, and consider important aspects of the problem. The DEA's rescheduling determination must survive this "arbitrary and capricious" review, a deferential but meaningful standard that requires reasoned decision-making. The Single Convention on Narcotic Drugs of 1961, a treaty ratified by the United States, requires parties to maintain controls on cannabis. State plaintiffs opposing rescheduling argue that Schedule III classification violates U.S. treaty obligations by insufficiently restricting a substance that remains in Schedule I under the Convention. However, the treaty allows parties to adopt stricter domestic controls and doesn't mandate specific scheduling classifications under domestic law. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that treaties are the "supreme Law of the Land," though courts have generally held that later-enacted federal statutes can supersede treaty obligations domestically. The Tenth Amendment reserves to states powers not delegated to the federal government, creating the constitutional foundation for state cannabis legalization despite federal prohibition. States argue they retain police powers to regulate health, safety, and welfare within their borders, including the authority to legalize and regulate cannabis. The anti-commandeering doctrine, established in cases like Printz v. United States (1997) and Murphy v. NCAA (2018), prohibits the federal government from compelling states to enforce federal law. This doctrine explains how states can decline to criminalize cannabis without violating the CSA, though it doesn't prevent federal enforcement within state borders. The Commerce Clause, Article I, Section 8, Clause 3, grants Congress authority to regulate interstate commerce, which the Supreme Court has interpreted broadly to include intrastate activities that substantially affect interstate commerce. In Gonzales v. Raich (2005), the Court upheld federal authority to prosecute intrastate medical marijuana cultivation under the CSA, finding that local cannabis production could affect the interstate marijuana market. This precedent supports federal scheduling authority but doesn't address whether the DEA's specific classification decisions are scientifically sound or procedurally proper. Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses from deducting ordinary business expenses if they traffic in Schedule I or II controlled substances. Rescheduling to Schedule III would eliminate this tax penalty for cannabis businesses, fundamentally altering industry economics. The provision has generated substantial litigation, with cannabis operators challenging its application through tax courts. Rescheduling would moot these challenges while creating an estimated $1.8 billion annual tax benefit for the industry.

State-by-State Breakdown

The legal challenges to cannabis rescheduling reflect a stark geographic divide between states that have embraced legalization and those maintaining prohibition, with litigation positions closely tracking state policy choices.

States Opposing Rescheduling

Nebraska, Kansas, Idaho, Wyoming, South Carolina, Alabama, Mississippi, Louisiana, Tennessee, Kentucky, Indiana, Oklahoma, and South Dakota form the core coalition challenging rescheduling in federal court. These states maintain comprehensive cannabis prohibition with no legal medical marijuana programs (though South Dakota voters approved medical cannabis in 2020, implementation has faced legal challenges). The coalition argues that rescheduling would undermine their enforcement efforts, increase cross-border trafficking, and contradict their policy determinations that cannabis poses significant public health risks. Indiana joined the lawsuit in May 2026, with Attorney General arguing that federal rescheduling would pressure the state legislature to reconsider its prohibition stance and complicate law enforcement.

States Supporting Rescheduling or Descheduling

California, Colorado, Washington, Oregon, Michigan, Illinois, New York, New Jersey, Massachusetts, and Nevada filed amicus briefs supporting rescheduling or arguing for complete descheduling. These states operate mature recreational cannabis markets with combined annual sales exceeding $18 billion. California's brief, filed in September 2024, emphasized that the state's 1,200+ licensed retailers serve 8 million consumers monthly and that Schedule III classification would reduce federal-state conflicts while maintaining appropriate controls. Colorado argued that eight years of recreational legalization data demonstrates cannabis's relative safety compared to Schedule I substances like heroin.

States With Medical-Only Programs

Florida, Ohio, Pennsylvania, Maryland, Missouri, and Arizona operate medical marijuana programs but haven't legalized recreational use. These states generally support rescheduling to Schedule III as consistent with their medical determinations, though they oppose arguments for full descheduling. Florida's brief noted that the state's 800,000+ registered medical marijuana patients—the nation's second-largest program—demonstrate accepted medical use. Ohio emphasized that its November 2023 recreational legalization ballot measure, which passed with 57% support, reflected evolving public understanding of cannabis risks.

States in Transition

Minnesota, Delaware, Rhode Island, and Connecticut recently legalized recreational cannabis and are implementing regulatory frameworks. These states filed briefs supporting rescheduling while emphasizing the need for federal policy clarity to guide their emerging markets. Minnesota's brief, filed in January 2025, argued that the state's August 2023 legalization law relied on assumptions about eventual federal rescheduling and that Schedule I maintenance would create operational challenges for the 300+ businesses receiving provisional licenses.

Market and Business Implications

The legal uncertainty surrounding DEA rescheduling has created a $12 billion valuation gap in cannabis equity markets and frozen an estimated $3.2 billion in pending mergers and acquisitions as operators await clarity on tax treatment and banking access. Multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs face dramatically different financial futures depending on litigation outcomes. According to Viridian Capital Advisors, Schedule III rescheduling would improve cannabis industry EBITDA margins by an average of 8-12 percentage points by eliminating 280E tax burdens, potentially adding $2.1 billion in annual profitability across publicly traded operators. However, continued Schedule I classification would maintain the status quo of effective tax rates exceeding 70% for plant-touching businesses, limiting growth capital and competitive positioning against illicit markets. The wholesale cannabis market has experienced price compression of 40-60% since 2021 in mature markets like Oregon, California, and Colorado, driven by oversupply and regulatory costs. Rescheduling could accelerate consolidation by improving access to bankruptcy protection (currently unavailable to businesses trafficking in Schedule I substances under 11 U.S.C. § 109), enabling distressed asset sales and market rationalization. Conversely, legal challenges that delay or prevent rescheduling could force hundreds of marginal operators into insolvency without bankruptcy relief, potentially increasing illicit market share. Banking access remains severely constrained under Schedule I classification, with fewer than 800 of the nation's 4,500+ banks willing to serve cannabis clients despite FinCEN guidance. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, has passed the House seven times but stalled in the Senate. Schedule III classification wouldn't directly resolve banking barriers, as cannabis would remain federally illegal, though it could reduce institutional risk perceptions and encourage broader financial services participation. The legal challenges create additional uncertainty that banks cite when declining cannabis accounts. Capital markets have priced in substantial rescheduling probability, with the MSOS cannabis ETF rising 87% between October 2023 (when HHS's recommendation leaked) and May 2024 (when the NPRM published). However, the index declined 34% between June 2024 and May 2026 as legal challenges mounted and timelines extended. Institutional investors including hedge funds and private equity firms have committed an estimated $4.7 billion to cannabis deployment contingent on rescheduling, capital that remains sidelined during litigation. According to Cantor Fitzgerald equity research, each quarter of rescheduling delay costs the industry approximately $450 million in foregone tax savings and growth investment.

What Experts Say

Legal scholars, medical researchers, and industry analysts offer sharply divergent assessments of the rescheduling litigation's likely outcomes and implications, reflecting deep disagreement about cannabis's risks and appropriate regulatory framework. Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," said in a February 2025 law review article that the DEA faces a "nearly impossible task" defending Schedule III classification against challenges from both directions. According to Mikos, the agency must simultaneously argue that cannabis is dangerous enough to warrant Schedule III controls while safe enough to move from Schedule I, a position he described as "legally and scientifically precarious." Mikos predicted that courts would likely defer to the DEA's expertise under Chevron deference principles, though he noted that the Supreme Court's recent skepticism toward administrative agency authority could complicate that analysis. Bertha Madras, professor of psychobiology at Harvard Medical School and former deputy director of the White House Office of National Drug Control Policy, testified at the December 2024 DEA hearing that rescheduling to Schedule III "ignores substantial evidence of cannabis's addiction potential and cognitive harms, particularly among adolescents." Madras cited longitudinal studies showing that regular cannabis use beginning in adolescence correlates with IQ declines of 6-8 points and increased rates of psychotic disorders. She argued that the HHS evaluation improperly dismissed this evidence and that courts should find the DEA's reliance on that evaluation arbitrary and capricious. Ziva Cooper, professor of clinical neurobiology at Columbia University and director of the UCLA Center for Cannabis and Cannabinoids, provided contrary testimony emphasizing that "cannabis's safety profile compares favorably to legal substances including alcohol, tobacco, and many prescription medications." Cooper noted that cannabis has never caused a fatal overdose, unlike opioids which kill more than 80,000 Americans annually, and that withdrawal symptoms are mild compared to alcohol or benzodiazepines. She argued that Schedule III classification, while imperfect, would appropriately recognize medical utility while maintaining controls on distribution. Shane Pennington, partner at Vicente LLP and counsel to several industry plaintiffs, said in a May 2025 legal podcast that the multi-state coalition opposing rescheduling faces "significant procedural and substantive hurdles." According to Pennington, states lack standing to challenge federal drug scheduling decisions absent concrete injury beyond generalized law enforcement concerns, and courts have historically granted DEA substantial deference on scientific determinations. However, Pennington noted that the cannabis industry's challenges arguing for descheduling face equally difficult obstacles, as courts have never required agencies to adopt the least restrictive regulatory option when multiple approaches could be reasonable. John Hudak, deputy director of the Brookings Institution's Center for Effective Public Management, wrote in a March 2026 analysis that the litigation "reflects the fundamental incoherence of federal cannabis policy in an era when 38 states have legalized medical use and 24 have legalized recreational use." Hudak argued that Schedule III classification represents a "political compromise rather than a scientific determination," attempting to thread the needle between prohibition advocates and legalization supporters. He predicted that regardless of litigation outcomes, Congress would eventually need to legislatively resolve cannabis's federal status through comprehensive reform rather than administrative rescheduling. Sam Kamin, professor at the University of Denver Sturm College of Law, said in testimony before the House Judiciary Committee in January 2026 that the rescheduling litigation highlights "the limits of administrative law as a tool for resolving fundamental policy disputes." According to Kamin, the CSA's scheduling criteria were designed for substances with clear pharmacological profiles and limited social use, not for a substance consumed by an estimated 49 million Americans annually with widespread state-level legalization. Kamin argued that courts should defer to the political branches to resolve cannabis policy rather than attempting to divine the "correct" schedule through judicial review of agency science.

What's Next

The legal challenges to DEA cannabis rescheduling will unfold across multiple federal circuits over the next 18-36 months, with potential Supreme Court review in 2027 or 2028 determining the ultimate outcome. The U.S. Court of Appeals for the Fifth Circuit, where the multi-state coalition filed its challenge, will likely hear oral arguments in the case during the fall 2026 term. The Fifth Circuit has a reputation as one of the most conservative appellate courts and has frequently ruled against federal agency authority in recent years. A three-judge panel will initially hear the case, with the possibility of en banc review by the full court if the panel decision is controversial. Legal observers expect a decision by spring 2027, though the timeline could extend if the court requests supplemental briefing or holds multiple argument sessions. The D.C. Circuit, where cannabis industry plaintiffs filed their challenges, operates on a similar timeline. The D.C. Circuit has particular expertise in administrative law and regularly reviews DEA scheduling decisions. Oral arguments are tentatively scheduled for August 2026, with a decision expected in late 2026 or early 2027. The D.C. Circuit's decision could conflict with the Fifth Circuit's ruling, creating a circuit split that would increase the likelihood of Supreme Court review. The DEA's administrative process continues in parallel with litigation. The agency must review the 43,000+ public comments, consider the hearing testimony, and issue a final rule. Administrative law requires the DEA to respond to significant comments and explain its reasoning for rejecting alternative approaches. This process typically takes 12-18 months after the comment period closes, suggesting a final rule in late 2025 or early 2026. However, the pending litigation could cause the DEA to delay finalizing the rule until courts resolve threshold legal questions about the agency's authority and process. If the DEA issues a final rule rescheduling cannabis to Schedule III before courts resolve the challenges, the rule would likely take effect 30 days after publication in the Federal Register unless courts issue a preliminary injunction. Plaintiffs opposing rescheduling would almost certainly seek such an injunction, arguing irreparable harm from immediate implementation. Courts balance four factors when considering preliminary injunctions: likelihood of success on the merits, irreparable harm, balance of equities, and public interest. The multi-state coalition would argue that immediate rescheduling would irreparably harm their law enforcement efforts and public health, while industry plaintiffs seeking descheduling would argue that continued Schedule III classification causes ongoing financial harm through 280E taxes and banking restrictions. The Supreme Court could intervene at multiple points. If circuit courts issue conflicting decisions, the Court would likely grant certiorari to resolve the split. Alternatively, if one circuit upholds the DEA's rescheduling and another strikes it down, the losing party would petition for Supreme Court review. The Court's recent administrative law jurisprudence, including the June 2024 decision overturning Chevron deference in Loper Bright Enterprises v. Raimondo, suggests the justices may be skeptical of broad agency authority. However, the Court has historically granted DEA substantial deference on drug scheduling decisions, creating uncertainty about how the justices would rule. Congress retains authority to legislatively reschedule or deschedule cannabis at any time, bypassing the administrative and judicial processes entirely. The Cannabis Administration and Opportunity Act, introduced in the Senate in 2023, would remove cannabis from the CSA entirely and establish a federal regulatory framework similar to alcohol. The bill has not advanced to a floor vote, though sponsors argue that the rescheduling litigation demonstrates the need for legislative clarity. The SAFE Banking Act, which would protect financial institutions serving cannabis businesses, has broader bipartisan support and could pass independently of comprehensive reform. Legislative action would moot the pending lawsuits, though the political dynamics make passage uncertain. International treaty obligations could constrain U.S. rescheduling options. The Single Convention on Narcotic Drugs requires parties to maintain controls on cannabis, though the treaty allows flexibility in implementation. If the U.S. reschedules cannabis to Schedule III, it would need to notify the International Narcotics Control Board and potentially seek amendments to treaty schedules. Canada and Uruguay, which have legalized recreational cannabis, navigated this process by formally reserving their positions under the treaty. The U.S. could adopt a similar approach, though state plaintiffs opposing rescheduling argue this would violate the Supremacy Clause's requirement that the U.S. comply with treaty obligations.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking, Federal Register Vol. 89, No. 97 (May 21, 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-10633/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to DEA on Cannabis Rescheduling (August 2023) — https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-dea-reschedule-marijuana.html
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• Administrative Procedure Act, 5 U.S.C. § 551 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title5/pdf/USCODE-2021-title5-partI-chap5.pdf
• Single Convention on Narcotic Drugs (1961) — https://www.unodc.org/pdf/convention_1961_en.pdf
• Internal Revenue Code Section 280E — https://www.law.cornell.edu/uscode/text/26/280E
• National Cannabis Industry Association Industry Statistics — https://thecannabisindustry.org/ncia-news-resources/state-by-state-policies/
• DEA Drug Scheduling Petitions and Decisions — https://www.deadiversion.usdoj.gov/schedules/index.html
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (Updated 2024) — https://crsreports.congress.gov/product/pdf/R/R44782

Update — June 1, 2026: MMJ International Holdings Joins D.C. Circuit Rescheduling Challenge

MMJ International Holdings filed a motion to intervene in the consolidated D.C. Circuit Court of Appeals challenge to the DEA's marijuana rescheduling order, according to a June 1, 2026 company announcement. The publicly traded cannabis operator joined more than two dozen petitioners challenging the DEA's final rule moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. MMJ International operates licensed cultivation and dispensary facilities across multiple state markets.

The company's intervention brief focuses on operational and financial harms stemming from the rescheduling framework's continued federal prohibition on interstate commerce and banking access. According to the filing, Schedule III classification preserves criminal penalties for unlicensed distribution while failing to address 280E tax burdens that prevent state-licensed operators from deducting ordinary business expenses. MMJ International reported $4.2 million in non-deductible operating expenses in fiscal year 2025 under the existing 280E regime.

The D.C. Circuit consolidated 27 separate petitions filed between January and May 2026 challenging various aspects of the DEA's rescheduling order, which took effect on January 15, 2026. Petitioners include state attorneys general, tribal governments, medical cannabis patients, and licensed operators. Oral arguments are scheduled for September 2026, with briefing deadlines running through August 15.

MMJ International's legal team argued that the rescheduling order violates the Administrative Procedure Act by failing to adequately address public comments on interstate commerce restrictions and banking reform. The company seeks full descheduling or Schedule V placement to align federal policy with state regulatory frameworks. The intervention motion cited $847 million in aggregate 280E tax liability across the licensed cannabis industry in 2025, according to industry financial data submitted to the court.